- Research article
- Open Access
- Open Peer Review
Low frequency of the TIRAPS180L polymorphism in Africa, and its potential role in malaria, sepsis, and leprosy
- Lutz Hamann1, 2Email author,
- Oliver Kumpf3,
- Ron P Schuring4,
- Erkan Alpsoy5,
- George Bedu-Addo6,
- Ulrich Bienzle^2,
- Linda Oskam4,
- Frank P Mockenhaupt2 and
- Ralf R Schumann1
© Hamann et al; licensee BioMed Central Ltd. 2009
- Received: 28 August 2008
- Accepted: 14 July 2009
- Published: 14 July 2009
The Toll-like receptors (TLRs) mediate innate immunity to various pathogens. A mutation (S180L) in the TLR downstream signal transducer TIRAP has recently been reported to be common in Europeans and Africans and to roughly half the risks of heterogeneous infectious diseases including malaria, tuberculosis, bacteremia, and invasive pneumococal disease in heterozygous mutation carriers.
We assessed the TIRAP S180L variant by melting curve and RFLP analysis in 1095 delivering women from malaria-endemic Ghana, as well as in a further 1114 individuals participating in case control studies on sepsis and leprosy in Germany, Turkey and Bangladesh.
In Ghana, the TIRAP S180L polymorphism was virtually absent. In contrast, the mutation was observed among 26.6%, 32.9% and 12% of German, Bangladesh and Turkish controls, respectively. No significant association of the heterozygous genotype with sepsis or leprosy was observed. Remarkably, homozygous TIRAP 180L tend to increase the risk of sepsis in the German study (P = 0.04).
A broad protective effect of TIRAP S180L against infectious diseases per se is not discernible.
- Single Nucleotide Polymorphism
- Invasive Pneumococcal Disease
- Falciparum Infection
Almost sixty years ago, J. Haldane suggested that malaria had selected hemoglobinopathies to high gene frequencies in malaria-endemic areas due to the protection they confer against this life-threatening disease . This "malaria hypothesis" is now the paradigm of evolutionary selection by infectious diseases, and malaria is considered the strongest known force in this regard . Continuing this early finding a major goal of medical genetics during the last two decades has been to unravel the influence of host's genetics on susceptibility or pathogenesis of common diseases and find specific associations of human genetic variations with these diseases [3, 4].
While in case of malaria it is obvious that genetic variations of the erythrocyte – target of the malaria parasite Plasmodium – can prevent or modulate disease, host proteins involved in pathogen recognition and defense may also be of pathophysiological importance in malaria  and other infectious diseases. The discovery of the toll-like receptor (TLR) system and of central signaling molecules has improved our understanding of host-pathogen interaction in many infectious diseases . Genetic variations within this system have been found and some relate to disease susceptibility and manifestation . In vitro and in vivo data point to TLRs -2, -4 and -9 to be central for Plasmodium recognition and subsequent inflammatory host responses [8–14]. The Toll-interleukin 1 receptor (TIR) domain containing adaptor protein (TIRAP, also known as Mal) mediates downstream signaling of TLR-2 and TLR-4, eventually inducing pro-inflammatory responses . Recently, an S180L single nucleotide polymorphism (SNP) of TIRAP has been reported to diminish TLR-2 signaling and to occur at a prevalence of some 30% among healthy subjects in the UK and in 2–6% among individuals from West and East Africa. Heterozygosity for this SNP has been claimed to confer protection against malaria and severe malaria to an extent comparable to HbAS, and in addition, to more than halve the risks of bacteremia and tuberculosis in African populations . In an attempt to verify these broad and evolutionary important effects, we screened for TIRAP S180L in a Ghanaian population exposed to holoendemic malaria transmission, and examined the role of the SNP in Caucasian and Asian patients affected by sepsis or leprosy.
Detailed description of sepsis patients
Cohort (n = 223)
(n = 170)
(n = 43)
(n = 10)
No (%) of patients
No (%) of patients
Type of surgery
Limb and others
No (%) of infections
Type of Infection
Urinary tract infections
No (%) of infections c
No (%) of patients
Morbidity and Mortality
Sepsis without organ dysfunction
Severe sepsis and septic shock
The study protocols were reviewed and approved by the Committee on Human Research Publication and Ethics, School of Medical Sciences, University for Science and Technology, Kumasi, Ghana, and by the human subject review committees at Humboldt-University Berlin, Germany, and Akdeniz University, Antalya, Turkey, and the institutional guidelines were followed in conducting this study. For the Bangladesh study, written approval was granted by the Ethical Review Committee of Bangladesh Medical Research Council (BMRC/ERC/2001–2004/799 and BMRC/ERC/2004–2007/120.
Sample size calculations
For this exploratory survey, no definite sample size calculation was performed. However, considering published average prevalences of TIRAP S180L of 30% in Caucasians, Asians and 4% in Africans , and 33% in Bangladesh, this study had a power of 80% at a 95% confidence level to display risk reductions (odds ratios) of 0.27, 0.50, 0.22, and 0.56 for malaria, sepsis, leprosy (Turkey) and leprosy (Bangladesh), respectively.
DNA was extracted from blood by standard techniques. Genotyping for TIRAP S180L was carried out by melting curve analysis employing the Lightcycler 480 device (Roche Diagnostics, Mannheim, Germany) using the following primers and probes: sense primer: GCCAGGCACTGAGCAGTAGT, antisense primer: GTGGGTAGGCAGC-TCTTCTG, anchor probe: Red640-GATGGTGCAGCCCTCGGCCCC, and sensor probe: AGGCCCAACAGCAGGG-FL. The melting peaks are at 53°C and 62°C for the wildtype and the mutated sequences, respectively. Due to secondary structures and allele biased amplification within the region of this SNP, analysis of heterozygous genotypes may sometimes result in false homozygous results. Therefore, all mutated samples were reanalysed by conventional RFLP method described by Khor et al. . Genomic DNA was amplified with following primers: CTCCAGGGGCCGAGGGCTGCACCATCCCCATGCTG and TACT-GTAGCTGAATCCCGTTCC. The resulting PCR product was digested with BstXI and analysed by gel electrophoresis.
Comparison of proportions of heterozygous and wild type individuals was done by χ2 or Fisher's exact test, as applicable.
Frequency of the TIRAP-S180L variant in different populations
No. of individuals with genotype (%)
Population and disease
Allele Frequency (%)
Ghana, delivering women
P. falciparum positive
P. falciparum negative
In the German sepsis study, the heterozygous TIRAP S180L genotype was frequent but there was no significant association with the risk of developing sepsis. Nevertheless, heterozygosity was slightly more frequent in controls than in patients, 25.5% versus 19.3%, respectively (P = 0.19, Table 2), potentially indicating some advantage when the heterozygous genotype was present. In contrast, the homozygous TIRAP 180L genotype was significantly more frequent in patients, (4.5 versus 1.1%, P = 0.04, Table 2), indicating this genotype to potentially be a risk factor for developing sepsis. This is also being reflected by a trend showing a slightly increased frequency of the homozygous TIRAP 180L within the patient group of severe sepsis and septic shock compared to septic patients without organ dysfunction (7.4 versus 1.7%, P = 0.1, Table 1).
Both leprosy studies showed no significant association either of heterozygosity or homozygosity with leprosy (Table 2). Again, we found a slightly enhanced frequency of heterozygosity in controls from Bangladesh compared to leprosy patients, 31.4% versus 25.9% (P = 0.22), also potentially indicating some degree of advantage of the heterozygous mutation for leprosy. The small study from Turkey showed controversial results. We observed heterozygous TIRAP S180L in 11% of control individuals, but more frequently, 22%, in leprosy patients (Table 2). However, the sample number of this study is too low for significant conclusions.
We here report the virtual absence of a putatively malaria-protective SNP in an area of holoendemic malaria transmission in West Africa. This not only contrasts the published prevalence among African populations of 2–6% , also, and more importantly, it argues against clinical-epidemiological relevance in malaria and against the hypothesis that malaria has exerted significant positive selective pressure on the presence of this SNP. According to Haldane's malaria hypothesis [1, 2], higher frequencies of this SNP than reported and observed here should be expected in highly malaria-endemic areas considering the postulated protective effect against this disease of 42–96% . We are at loss to explain the discrepancy between the reported prevalences of 5.9 and 3.4% among control populations in such distantly located African countries as The Gambia and Kenya and the 0.1% we found in Ghana. Nevertheless, the latter figure – particularly when facing the 15–30% in Caucasians – strongly argues against an expected positive selection of a malaria-protective trait in Africa. The absence of homozygosity for TIRAP 180L in the African studies could suggest a state of balanced polymorphism due to a yet unknown disadvantage in homozygotes and acting against relevant allele frequencies. A homozygous disadvantage has been claimed for Caucasians with respect to a slightly increased risk for invasive pneumococcal disease and pneumococcal empyema . One theoretical limitation of the present study is that we examined predominantly asymptomatic women with or without placental P. falciparum infection. Thus, potential protective features of the SNP could be missed in individuals with non-severe malaria. However, in The Gambia the risk reductions in terms of severe malaria and "general malaria" were very similar . Ultimately, the extremely low prevalence of heterozygous TIRAP S180L in Ghana, where malaria endemicity is among the highest in the world argues against attempts to replicate its putatively protective effect: Given the observed prevalence of heterozygosity of 0.1%, a study able to confirm the reported risk reduction would need to comprise several tens of thousands of individuals to have sufficient statistical power. This, in turn, is even another argument against the presumed clinical relevance of this mutation in Africa.
Heterozygosity for TIRAP S180L has been suggested to be protective not only against malaria but also against bacterial infections including invasive pneumococcal disease, pneumococcal empyema, overall and pneumococcal bacteremia, and tuberculosis . In our study populations from Germany, Bangladesh, and Turkey we found allele frequencies of 19, 17, and 6.5%, respectively. However, we only found very limited evidence for heterozygosity being protective in both, sepsis and leprosy patients. Likewise, within the subgroup of sepsis patients suffering from pneumonia no significant protection of heterozygosity could be observed (Table 1). In the sepsis study, the proportion of heterozygous TIRAP S180L genotype seem to be influenced by co-existing diseases such as Diabetes and renal pathology, however, there is no significant difference (Table 1). In contrast, we found at borderline significance an increased frequency of homozygosity in sepsis patients (p = 0.04, Table 2). This is in line with the data reported by Khor et al. , who also showed an increased, but not significant, frequency of homozygosity in invasive pneumococcal disease and pneumococcal empyema. However, larger studies are needed to verify whether heterozygosity is protective or homozygosity is a risk factor. Remarkably also, in a recent study from Ghana, Russia and Indonesia, TIRAP S180L also failed to show any association of heterozygosity with tuberculosis in any population. Of note, this study also found a very low allele frequency for the TIRAP S180L of only 0.08% in Ghana .
While the TLR system has been shown to be critically involved in susceptibility to and manifestation of malaria, we found a very low frequency of the S180L mutation in the TLR downstream mediator TIRAP in a highly endemic region arguing against a major role of this SNP in malaria. In our study populations with a relative high prevalence of the TIRAP S180L, we found a trend but no significant protection of heterozygosity in sepsis and leprosy. In contrast, in sepsis TIRAP 180L homozygosity appears to be a risk factor for disease. Taking together our data and those of Khor et al. , we suggest that there might be a slight protective effect of heterozygous TIRAP S180L in several diseases. At the same time homozygous TIRAP 180L appears to be a risk factor for the same diseases. The specific role of TIRAP S180L needs further investigation.
We thank the patients and controls participating in this study. Financial support was provided by Charité – Universitätsmedizin Berlin (grant 2007-486) and the German Research Foundation (to R.R.S). We acknowledge the excellent technical assistance of Diana Woellner and Fränzi Creutzburg (Institute for Microbiology, Charité, Berlin). The Colep study was funded by the American Leprosy Missions and The Leprosy Mission Internaional.
- Haldane J: The rate of mutation of human genes. Hereditas. 1949, 35: 267-272.View ArticleGoogle Scholar
- Kwiatkowski DP: How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Genet. 2005, 77 (2): 171-192. 10.1086/432519.View ArticlePubMedPubMed CentralGoogle Scholar
- Stranger BE, Forrest MS, Clark AG, Minichiello MJ, Deutsch S, Lyle R, Hunt S, Kahl B, Antonarakis SE, Tavare S, et al: Genome-wide associations of gene expression variation in humans. PLoS Genet. 2005, 1 (6): e78-10.1371/journal.pgen.0010078.View ArticlePubMedPubMed CentralGoogle Scholar
- Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird CP, de Grassi A, Lee C, et al: Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science. 2007, 315 (5813): 848-853. 10.1126/science.1136678.View ArticlePubMedPubMed CentralGoogle Scholar
- Schofield L, Grau GE: Immunological processes in malaria pathogenesis. Nat Rev Immunol. 2005, 5 (9): 722-735. 10.1038/nri1686.View ArticlePubMedGoogle Scholar
- Creagh EM, O'Neill LA: TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol. 2006, 27 (8): 352-357. 10.1016/j.it.2006.06.003.View ArticlePubMedGoogle Scholar
- Schröder NWJ, Schumann RR: Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis. 2005, 5 (3): 156-164.View ArticlePubMedGoogle Scholar
- Coban C, Ishii KJ, Uematsu S, Arisue N, Sato S, Yamamoto M, Kawai T, Takeuchi O, Hisaeda H, Horii T, et al: Pathological role of Toll-like receptor signaling in cerebral malaria. Int Immunol. 2007, 19 (1): 67-79. 10.1093/intimm/dxl123.View ArticlePubMedGoogle Scholar
- Krishnegowda G, Hajjar AM, Zhu J, Douglass EJ, Uematsu S, Akira S, Woods AS, Gowda DC: Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J Biol Chem. 2005, 280 (9): 8606-8616. 10.1074/jbc.M413541200.View ArticlePubMedGoogle Scholar
- McCall MB, Netea MG, Hermsen CC, Jansen T, Jacobs L, Golenbock D, Ven van der AJ, Sauerwein RW: Plasmodium falciparum infection causes proinflammatory priming of human TLR responses. J Immunol. 2007, 179 (1): 162-171.View ArticlePubMedGoogle Scholar
- Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, Oh NR, Otchwemah RN, Dietz E, Ehrhardt S, Schroder NW, et al: Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci USA. 2006, 103 (1): 177-182. 10.1073/pnas.0506803102.View ArticlePubMedGoogle Scholar
- Mockenhaupt FP, Hamann L, von Gaertner C, Bedu-Addo G, von Kleinsorgen C, Schumann RR, Bienzle U: Common polymorphisms of toll-like receptors 4 and 9 are associated with the clinical manifestation of malaria during pregnancy. J Infect Dis. 2006, 194 (2): 184-188. 10.1086/505152.View ArticlePubMedGoogle Scholar
- Parroche P, Lauw FN, Goutagny N, Latz E, Monks BG, Visintin A, Halmen KA, Lamphier M, Olivier M, Bartholomeu DC, et al: Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci USA. 2007, 104 (6): 1919-1924. 10.1073/pnas.0608745104.View ArticlePubMedPubMed CentralGoogle Scholar
- Schumann RR: Malarial fever: hemozoin is involved but Toll-free. Proc Natl Acad Sci USA. 2007, 104 (6): 1743-1744. 10.1073/pnas.0610874104.View ArticlePubMedPubMed CentralGoogle Scholar
- Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, Hoshino K, Takeuchi O, Kobayashi M, Fujita T, et al: Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature. 2002, 420 (6913): 324-329. 10.1038/nature01182.View ArticlePubMedGoogle Scholar
- Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, Frodsham AJ, Walley AJ, Kyrieleis O, Khan A, et al: A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet. 2007, 39 (4): 523-528. 10.1038/ng1976.View ArticlePubMedPubMed CentralGoogle Scholar
- Hommerich L, von Oertzen C, Bedu-Addo G, Holmberg V, Acquah PA, Eggelte TA, Bienzle U, Mockenhaupt FP: Decline of placental malaria in southern Ghana after the implementation of intermittent preventive treatment in pregnancy. Malar J. 2007, 6: 144-10.1186/1475-2875-6-144.View ArticlePubMedPubMed CentralGoogle Scholar
- Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003, 31 (4): 1250-1256. 10.1097/01.CCM.0000050454.01978.3B.View ArticlePubMedGoogle Scholar
- Moet FJ, Oskam L, Faber R, Pahan D, Richardus JH: A study on transmission and a trial of chemoprophylaxis in contacts of leprosy patients: design, methodology and recruitment findings of COLEP. Lepr Rev. 2004, 75 (4): 376-388.PubMedGoogle Scholar
- World Health Organization: WHO expert committee on leprosy, seventh report 1998. WHO Technical Report Series 874.Google Scholar
- Nejentsev S, Thye T, Szeszko JS, Stevens H, Balabanova Y, Chinbuah AM, Hibberd M, Vosse van de E, Alisjahbana B, van Crevel R, et al: Analysis of association of the TIRAP (MAL) S180L variant and tuberculosis in three populations. Nat Genet. 2008, 40 (3): 261-262. 10.1038/ng0308-261.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/10/65/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.